Form FDA 483 · Issued 2026-03-26
Newton Laboratories, Inc. — FDA Form 483 Analysis
FEI: 1051203 · Sector: Pharmaceuticals & Sterile/OTC Drugs (Homeopathic Drug Manufacturer) · Lead Investigator: Thomas W. Halvorsen
FDA Form 483 issued to Newton Laboratories, Inc. (FEI 1051203) on 2026-03-26 following an inspection of its homeopathic drug manufacturer operations in Georgia. The report documents 3 inspection observations centered on Incoming Ingredient Identity Testing & COA Qualification.
Get Full Annotated 483 Dossier + CAPA Checklist
Instant PDF + CFR Matrix ($79 vs. Redica's $289)
Need Help Fixing These 3 Citations?
Get matched with a vetted 21 CFR remediation consultant
Observation-by-Observation 21 CFR Breakdown (3)
Observation #1 · 21 CFR 212.50
Incoming Ingredient Identity Testing & COA Qualification
FIRST-TIME OBSERVATION
Adequate controls (general)
Inspector Observation Language: "Your firm lacks adequate production and process controls to ensure the consistent production of a PET drug that meets the applicable standards of identity, strength, quality and purity. Specifically,observed during inspection of Newton Laboratories, Inc. on 2026-03-26."
Plain-English Meaning: Failure to perform at least one test to verify the identity of every incoming dietary ingredient or raw component before use, or relying on a supplier's Certificate of Analysis (COA) without first qualifying the supplier.
Standard CAPA Remediation Path: Establish SOP-QA-004 requiring FTIR/HPLC/organoleptic identity testing on 100% of incoming dietary ingredient lots and annual audit + 3-lot confirmatory testing before relying on any vendor COA.
Observation #2 · 21 CFR 211.192
Incoming Ingredient Identity Testing & COA Qualification
FIRST-TIME OBSERVATION
Extent of discrepancy, failure investigations
Inspector Observation Language: "Investigations of [an unexplained discrepancy] [a failure of a batch or any of its components to meet any of its specifications] did not extend to [other batches of the same drug product] [other drug products that may have been associated with the specific failure or discrepancy]. Specifically, observed during inspection of Newton Laboratories, Inc. on 2026-03-26."
Plain-English Meaning: Failure to perform at least one test to verify the identity of every incoming dietary ingredient or raw component before use, or relying on a supplier's Certificate of Analysis (COA) without first qualifying the supplier.
Standard CAPA Remediation Path: Establish SOP-QA-004 requiring FTIR/HPLC/organoleptic identity testing on 100% of incoming dietary ingredient lots and annual audit + 3-lot confirmatory testing before relying on any vendor COA.
Observation #3 · 21 CFR 212.30(a)
Personnel GMP Training, Gowning & Hygienic Practices
FIRST-TIME OBSERVATION
Orderly handling, prevention of mix-ups, prevention of contamination
Inspector Observation Language: "Your facilities are not adequate to ensure [the orderly handling of materials and equipment] [the prevention of mix-ups] [the prevention of contamination of equipment or product by substances, personnel, or environmental conditions] that could reasonably be expected to have an adverse effect on product quality. Specifically, observed during inspection of Newton Laboratories, Inc. on 2026-03-26."
Plain-English Meaning: Operators performing manufacturing or QA tasks without documented GMP/SOP training, or observed gowning/hygiene deviations in production rooms.
Standard CAPA Remediation Path: Maintain role-based SOP training matrices signed prior to independent floor assignment and annual cGMP refresher assessments.